Search results
Astena Theraputics' investigational gene therapy, ATSN-101, has shown promising long-term results in an early clinical trial for LCA1, a sever inherited retinal disease caused by mutations in the GUCY2D gene.
Beacon Therapeutics has announced positive results from its phase 2/3 VISTA trial of laru-zova, an experimental gene therapy for X-linked retinitis pigmentosa (XLRP). The findings mark a significant step forward for a condition that currently has no approved treatments.
VeonGen has reported encouraging early results from a clinical trial of VG801, an investigational gene therapy for Startgardt disease, a genetic retinal condition that currently has no approved treatments.
Are you affected by inherited sight loss? We are here to help.
Our vision is a world where everyone with inherited sight loss is able to live a fulfilling life.
If you, or a close relative, are living with a genetic sight loss condition, there may be a chance that your children will inherit it.
Dr Nikolas Pontikos is a Senior Research Fellow at UCL Institute of Ophthalmology, and has been working on inherited retinal conditions for several years.
Join #TeamRetinaUK for an unforgettable Kiltwalk adventure in Glasgow, Aberdeen, Dundee or Edinburgh, throughout 2026.
